Table 1 Volunteers characteristics and vaccination history.
| Â | Volunteer id | Gender/age range | study arm | GRAd-COV2 dose (vpa) | Pfizer/AZ dose(s) study week |
|---|---|---|---|---|---|
Pfizer x 2 | A | M/26–30 y | 2B | 1 × 1011 vp | Pfizer x 2, week 16 &19 |
Pfizer x 2 | B | M/21–25 y | 3B | 2 × 1011 vp | Pfizer x 2, week 19 & 22 |
Pfizer x 2 | C | M/76–80 y | 5B | 1 × 1011 vp | Pfizer x 2, week 14 &−17 |
Pfizer x 1 | D | M/71–75 y | 4B | 5 × 1010 vp | Pfizer x 1, week 22 |
Pfizer x 1 | E | M/71–75 y | 6B | 2 × 1011 vp | Pfizer x 1, week 17†|
Pfizer x 1 | F | M/21–25 y | 2B | 1 × 1011 vp | Pfizer x 1, week 24 |
ChAdOx1 ×1 | G | M/76–80 y | 4B | 5 × 1010 vp | AZ x 1, week 21 |
ChAdOx1 ×1 | H | M/71–75 y | 5B | 1 × 1011 vp | AZ x 1, week 21 |
